Igm Biosciences, INC Form 4 insider transactions
Director Elizabeth H.Z. Thompson acquired 1,452 shares of IGM Biosciences common stock on March 29, 2024, as partial payment of a quarterly retainer.
Director M Kathleen Behrens acquired 3,078 shares of IGM Biosciences common stock as part of a quarterly retainer, while also reporting indirect ownership through various trusts.
Redmile Group, LLC reports adjustments to its beneficial ownership of IGM Biosciences stock due to an in-kind distribution and a grant of restricted stock units.
Baker Bros. Advisors LP reports acquisition of restricted stock units in IGM Biosciences on behalf of affiliated funds due to director retainer fees.
CEO Fred Schwarzer reports acquisition of restricted stock units (RSUs) and disposition of common stock.
Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports acquisition of restricted stock units (RSUs) and disposal of common stock.
Baker Bros. Advisors LP and affiliated entities report acquiring additional shares of IGM Biosciences (IGMS) common stock across several transactions in late March 2024, increasing their beneficial ownership.
Steven Weber, Principal Accounting Officer of IGM Biosciences, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
Chris H Takimoto, Chief Medical Officer of IGM Biosciences, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
IGM Biosciences CFO Misbah Tahir sold shares of common stock on March 13 and 14, 2024, to cover tax withholding obligations related to vesting restricted stock units.
IGM Biosciences CEO Fred Schwarzer sold shares of common stock on March 13 and 14, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reported the sale of company stock to cover tax obligations related to vesting restricted stock units.
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, sold shares of common stock on March 13 and 14, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Redmile Group, through its managing director Mike Lee's board service at IGM Biosciences, acquired stock options, with Jeremy Green and Redmile disclaiming beneficial ownership except for their pecuniary interest.
Michael Lee, a director of IGM Biosciences, was granted stock options for 29,400 shares of common stock at an exercise price of $9.95 on March 12, 2024.
Principal Accounting Officer Steven Weber of IGM Biosciences reported the acquisition of 18,750 restricted stock units and 37,500 stock options, as well as the disposal of 27,500 common stock shares.
Chris H Takimoto, Chief Medical Officer of IGM Biosciences, reports the acquisition of restricted stock units and stock options, along with the disposal of some shares.
Form 4: IGM Biosciences CFO Misbah Tahir Reports Acquisition and Disposal of Shares and Stock Options
CFO of IGM Biosciences, Misbah Tahir, reports acquiring restricted stock units and stock options while disposing of common stock.
CEO Fred Schwarzer acquired stock options and restricted stock units (RSUs) in IGM Biosciences, while also reporting indirect ownership through a family trust.
Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports acquiring restricted stock units and stock options while disposing of common stock.
Lisa Decker, Chief Business Officer of IGM Biosciences, reports the acquisition of restricted stock units and stock options.
Jakob Haldor Topsoe, a director of IGM Biosciences, acquired stock options for 29,400 shares on March 12, 2024.
Christina Teng Topsoe, a director at IGM Biosciences, acquired stock options for 29,400 shares on March 12, 2024.
Director Elizabeth H.Z. Thompson acquired stock options in IGM Biosciences, Inc. on March 12, 2024.
William Strohl, a director at IGM Biosciences, acquired stock options for 29,400 shares on March 12, 2024, according to a Form 4 filing.
Julie Hambleton, a director at IGM Biosciences, acquired stock options for 29,400 shares at an exercise price of $9.95 on March 12, 2024.
Director M Kathleen Behrens acquired stock options for 29,400 shares of IGM Biosciences on March 12, 2024.
Baker Bros. Advisors LP, along with related entities and individuals, reported the acquisition of non-qualified stock options in IGM Biosciences, Inc. on March 12, 2024.
Bruce Keyt, Chief Scientific Officer of IGM Biosciences, exercised stock options to acquire 3,026 shares of common stock at $0.93 per share on March 1, 2024.
Redmile Group, a significant shareholder in IGM Biosciences, converted 113,400 shares of non-voting common stock into voting common stock on February 28, 2024.